The State University of New York

Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Alma Mater Studiorum-universitá Di Bologna

Kenneth B Marcu

Xiang Li

Jianfei Yang

Jun Li

Margery A Connelly

Luigi Bolondi

Pásquale Chieco

Catia Giovannini

The present invention provides pharmaceutical compositions for the treatment of hepatocellular carcinoma (HCC) comprising Notch3 inhibitors and a chemotherapeutic agent, methods for the preparation of said compositions and a medical treatment comprising the administration of said pharmaceutical compositions in patients in need thereof.

Pharmaceutical composition and pharmaceutical kit for the treatment of hepatocellular carcinoma

A method for modulating NF-&#x3ba;B dependent gene transcription in a cell comprised of modulating IKK&#x3b1; protein activity in the cell. The present invention also provides siRNA compositions and methods thereof for modulating NF-&#x3ba;B dependent gene transcription.

Methods for modulating IKK&#x3b1; activity

The present invention provides isolated I&kgr;B kinases that regulate NF&kgr;B gene transcription that lack both a leucine zipper like &agr;-helix domain and helix-loop-helix domain. Also provided are the amino acid sequences of these kinases and the nucleotide sequence encoding these kinases, and other related protein and nucleic acid molecules.

Biologically active alternative form of the IKK&agr; I&kgr;B kinase

The present invention provides an isolated I&kgr;B kinase binding protein designated Y2H14 and functional equivalents therof. The amino acid sequence of Y2H14, the nucleotide sequence encoding Y2H14, and other related protein and nucleic acid molecules are also provided.

Y2H14 an IKK binding protein

The present invention provides an isolated I&kgr;B kinase binding protein designated Y2H35 and functional equivalents therof. The amino acid sequence of Y,H,the nucleotide sequence encoding Y2H35, and other related protein and nucleic acid molecules are also provided.

Y2H35 a strong IKK binding protein

The present invention provides an isolated I.kappa.B kinase designated IKK.alpha..DELTA.C, that regulates NF.kappa.B gene transcription. IKK.alpha..DELTA.C is an I.kappa.B protein kinase having a kinase domain, a leucine zipper like .alpha.-helix domain, and no helix-loop-helix domain. Also provided are the amino acid sequence of IKK.alpha..DELTA.C, the nucleotide sequence encoding IKK.alpha..DELTA.C, and other related protein and nucleic acid molecules. The invention provides antibodies specific for IKK.alpha..DELTA.C and methods of using the IKK.alpha..DELTA.C proteins of the invention in the development of antiinflammatory agents or immunosuppressants.

Biologically active alternative form of the ikka.alpha. I.kappa.B kinase

The present invention provides an isolated I.kappa.B kinase binding protein designated Y2H56 and functional equivalents therof. The amino acid sequence of Y2H56, the nucleotide sequence encoding Y2H56, and other related protein and nucleic acid molecules are also provided.

Y2H56 A strong IKK binding protein

The present invention provides an isolated I.kappa.B kinase binding protein designated Y2H61 and functional equivalents therof. The amino acid sequence of Y2H61, the nucleotide sequence encoding Y2H61, and other related protein and nucleic acid molecules are also provided.

Growing community of inventors

Stony Brook, NY, United States of America

Kenneth B Marcu